The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes

Kidney International

Volumn 73, Issue 5, 2008, Pages 630-636

  Mohanram, A ^a   Zhang, Z ^b   Shahinfar, S ^b   Lyle, P A ^b   Toto, R D ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anemia; Angiotensin receptor antagonist; End stage renal disease; Glomerular filtration rate; Hemoglobin; Losartan

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN; LOSARTAN; PLACEBO;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME;

EID: 39349106306     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002746     Document Type: Article

References (30)

1. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006; 29: S4-S42.
2. Ersoy A, Kahvecioglu S, Ersoy C et al. Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. Transplant Proc 2005; 37: 2148-2150.
3. Marathias KP, Agroyannis B, Mavromoustakos T et al. Hematocritlowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 2004; 4: 483-486.
4. Ok E, Akcicek F, Toz H et al. Comparison of the effects of enalapril and theophylline on polycythemia after renal transplantation. Transplantation 1995; 59: 1623-1626.
5. Julian BA, Brantley RR, Barker CV et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9: 1104-1108.
6. Yorgin PD, Belson A, Sanchez J et al. Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis 2002; 40: 1306-1318.
7. Ozbek N, Ozen S, Saatci U. Enalapril-induced anemia in a renal transplant patient. Acta Paediatr Jpn 1997; 39: 626-627.
8. Onoyama K, Kumagai H, Takeda K et al. Effects of human recombinant erythropoietin on anemia, systemic haemodynamics and renal function in predialysis renal failure patients. Nephrol Dial Transplant 1989; 4: 966-970.
9. Schwarzbeck A, Wittenmeier KW, Hällfritzsch U. Anaemia in dialysis patients as a side-effect of sartanes. Lancet 1998; 352: 286.
10. Sackey AH. Anaemia after enalapril in a child with nephrotic syndrome. Lancet 1998; 352: 285-286.
11. Richmond RS, Tallant EA, Gallagher PE et al. Angiotensin II stimulates arachidonic acid release from bone marrow stromal cells. J Renin Angiotensin Aldosterone Syst 2004; 5: 176-182.
12. Le Meur Y, Aldigier JC, Praloran V. Is plasma Ac-SDKP level a reliable marker of chronic angiotensin-converting enzyme inhibition in hypertensive patients? Hypertension 1998; 31: 1201-1202.
13. Mrug M, Stopka T, Julian BA et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100: 2310-2314.
14. Mohanram A, Zhang Z, Shahinfar S et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004; 66: 1131-1138.
15. Gouva C, Nikolopoulos P, Ioannidis JP et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
16. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
17. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
18. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
19. Ishani A, Weinhandl E, Zhao Z et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005; 45: 391-399.
20. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
21. Denton KM, Shweta A, Anderson WP. Preglomerular and postglomerular resistance responses to different levels of sympathetic activation by hypoxia. J Am Soc Nephrol 2002; 13: 27-34.
22. Brox AG, Mangel J, Hanley JA et al. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins. Transplantation 1998; 66: 1053-1058.
23. Le Meur Y, Lorgeot V, Comte L et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis 2001; 38: 510-517.
24. Macdougall IC. ACE inhibitors and erythropoietin responsiveness. Am J Kidney Dis 2001; 38: 649-651.
25. Morrone LF, Di Paolo S, Logoluso F et al. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Transplantation 1997; 64: 913-918.
26. Charrier S, Michaud A, Badaoui S et al. Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood 2004; 104: 978-985.
27. Keane WF, Brenner BM, de Zeeuw D et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63: 1499-1507.
28. Levey AS, Greene T, Kusek JW et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: 155A (abstract).
29. K/DOQI Work Group. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 6. Association of level of GFR with complications in adults. Am J Kidney Dis 2002; 39: S111-S169.
30. KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(5 Suppl 3): S11-S145.